• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine. The co-administration of CpG-ODN influenced protective activity of influenza M2e Vaccine.

Giuseppe

Emeritus
Vaccine. 2009 Apr 30. [Epub ahead of print]

The co-administration of CpG-ODN influenced protective activity of influenza M2e Vaccine.

Wu F, Yuan XY, Li J, Chen YH. - Laboratory of Immunology, Department of Biology, Tsinghua University; Beijing Key Laboratory for Protein Therapeutics, Beijing 100084, P.R. China.


In this report, we investigated the adjuvant effect of CpG-ODN on the immunogenicity and protective efficacy of influenza M2e peptide vaccine. We found that the addition of CpG-ODN 1826 into aluminum-adjuvant M2e peptide vaccine increased M2e-specific Th1 immune response, indicated by higher titers of M2e-specific IgG2a and more IFN-gamma-secreting lymphocytes.
However, according to the result from virus challenge, enhancement of M2e-specific Th1 immune response failed to increase the protection against influenza virus.
Moreover, when challenged with high dose of influenza virus, the addition of CpG-ODN even weakened the protective activity.
These results suggested that the intensity of immune responses was not simply correlated with protective activity of influenza M2e vaccine and more comprehensive criterion should be built up for the evaluation of M2e-based vaccine.

PMID: 19410621 [PubMed - as supplied by publisher]
-
------
 
Back
Top Bottom